Physician profile
Damon Hou
NPI 1578534350
$16,319.41
in general payments reported to CMS, 2019-2025
11 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $1,425 · 2021: $7,031 · 2022: $4,353 · 2023: $2,839 · 2024: $262 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,793 · Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,792.58 |
| Food and Beverage | $531.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $12,919.71 | 2021-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $2,777.18 | 2020-2021 | |
| Hologic Sales and Service, LLC | $222.81 | 2025 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Amag Pharmaceuticals, INC. | $117.48 | 2019 | |
| Renovia INC | $104.02 | 2021 | |
| Pfizer INC. | $62.43 | 2020-2024 | |
| Abbvie INC. | $57.96 | 2019 | |
| Sumitomo Pharma America, INC. | $27.66 | 2023 | Myfembree |
| Astellas Pharma US INC | $19.15 | 2024 | Veozah |
| Coopersurgical, INC. | $11.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.